The primary focus of EuroVacc’s scientific program is on facilitating translational research from discovery to early phase I/II clinical development.
With regard to the discovery program, EuroVacc’s lead vaccine platform is poxvirus-based vaccine, in particular NYVAC. The discovery program is carried out in collaboration with EuroVacc’s industrial partner Sanofi Pasteur and other academic partners
Clincal Development Program
With regard to the clinical development program, EuroVacc has sponsored or co-sponsored multiple phase I/II clinical trials in Europe and Africa, in both prophylactic and therapeutic settings. These trials are funded and co-funded by European Commission 5th and 7th Framework Programs, Agence nationale de recherches sur le sida et les hépatites virales (ANRS) of Inserm, International HIV Vaccine Trial Network (IAVI), and HIV Vaccine Trial Network(HVTN)/National Institute of Health (NIH).
EuroVacc also provides scientific project management support to large research consortia with the focus on facilitating the development from bench to clinic. To this end, EuroVacc engages a pool of experts from manufacturing, to regulatory to clinical trials.